Vivozon Pharmaceutical to launch 'Unafra' as a new surgical painkiller market in H2 2025
Vivozon Pharmaceutical plans to launch non-narcotic pain reliever Unafra in 2025, targeting KRW 100 billion in sales within five years. Unafra, approved by MFDS, is a first-in-class drug with multiple mechanisms for pain relief, aiming to replace opioid painkillers in post-surgical care. Vivozon is discussing domestic commercialization with Boryung and planning global expansion, including U.S. phase 3 trials.
Highlighted Terms
Related News
Vivozon Pharmaceutical plans to launch non-narcotic pain reliever Unafra in 2025, targeting KRW 100 billion in sales within five years. Unafra, approved by MFDS, is a first-in-class drug with multiple mechanisms for pain relief, aiming to replace opioid painkillers in post-surgical care. Vivozon is discussing domestic commercialization with Boryung and planning global expansion, including U.S. phase 3 trials.